Guerrero Ramiro's Form 4/A amendment
AmendedMAIA Biotechnology, Inc.MAIA · filed Mar 5, 2025
- Accession no.
- 0001127602-25-008317
- Filed
- Mar 5, 2025
- Trade date
- Feb 24, 2025
- Filing delay
- 9 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Feb 25, 2025
This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $110.0K. It was filed 9 days after the trade.
This amendment replaces 0001127602-25-006578 (filed Feb 25, 2025).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Guerrero RamiroCIK 0001913253 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 24, 2025 | Common Stock | PPurchaseAcquired | +73,333 | $1.50 | +$109,999.5 | 534,885.04 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 24, 2025 | Common Stock | PPurchaseAcquired | +73,333 | $1.87 | +$137,132.71 | 73,333 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plna on February 24, 2025.
- F2
This Form 4/A is being filed to correct the "Date Exercisable" and "Expiration Date" in Section 6 of Table II reported in the original Form 4 filed on February 25, 2025 as well as to correct the date of the Securities Purchase Agreement orginally referenced in the footnote 1 and 2 to "February 24, 2025".
- F3
These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options issued under the Issuer's 2021 Equity Incentive Plan on February 24, 2025. The options are exercisable beginning on the one-year anniversary of the issuance date and expire 6-years after the initial issuance date.